Trial · NCT02307513
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) | Placebo | 222.14 | Standard Error 15.886 | Ulcers*days | |
| Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) | Apremilast 30 mg BID | 129.54 | Standard Error 15.943 | Ulcers*days | |
| Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12 | Placebo | -15.9 | Standard Error 3.31 | mm | |
| Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12 | Apremilast 30 mg BID | -40.7 | Standard Error 3.34 | mm | |
| Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12 | Placebo | -5.41 | Standard Error 1.776 | Units on a scale | |
| Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12 | Apremilast 30 mg BID | -17.35 | Standard Error 1.796 | Units on a scale | |
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12 | Placebo | -0.4 | Standard Error 0.20 | Units on a scale | |
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12 | Apremilast 30 mg BID | -0.9 | Standard Error 0.20 | Units on a scale | |
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12 | Placebo | -0.7 | Standard Error 0.18 | Units on a scale | |
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12 | Apremilast 30 mg BID | -1.7 | Standard Error 0.18 | Units on a scale | |
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12 | Placebo | -0.7 | Standard Error 0.17 | Units on a scale | |
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12 | Apremilast 30 mg BID | -1.6 | Standard Error 0.17 | Units on a scale | |
| Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks | Placebo | 4.9 | Percentage of participants | ||
| Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks | Apremilast 30 mg BID | 29.8 | Percentage of participants | ||
| Time to Oral Ulcer Resolution (Complete Response) | Placebo | 8.1 | 95% Confidence Interval 4.7 to NA | Weeks | |
| Time to Oral Ulcer Resolution (Complete Response) | Apremilast 30 mg BID | 2.1 | 95% Confidence Interval 2.0 to 4.0 | Weeks | |
| Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12 | Placebo | 22.3 | Percentage of participants | ||
| Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12 | Apremilast 30 mg BID | 52.9 | Percentage of participants | ||
| Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12 | Placebo | -0.5 | Standard Error 0.66 | Units on a scale | |
| Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12 | Apremilast 30 mg BID | -3.5 | Standard Error 0.67 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02307513/results